Safety and efficacy of convalescent plasma as a therapy for SARS-CoV-2: A systematic review and meta-analysis

Background and Aims: The safety and efficacy of convalescent plasma therapy (CPT) in SARS-CoV-2 is promising but intriguing due to heterogeneity of published studies. We conducted this systematic review and meta-analysis of convalescent plasma use in COVID-19 to identify its safety and efficacy. Material and Methods: We comprehensively searched the databases - PubMed, Web of Science, Embase, and the Cochrane Library for journal papers published between December 2019 and January 2021 about the use of CPT in SARS-CoV-2, and performed a meta-analysis using random effects models and assessed the quality of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Results: Of 1529 records, 11 studies were eligible (five RCTs, two nonrandomized intervention trials, three prospective observational, and one retrospective), and all were conducted in confirmed patients of SARS-CoV-2. Out of the 11 studies, four investigated the effect of CPT on mortality, three on symptom alleviation, five on duration of hospital stay, four on time to discharge, three on the effect on viral clearance, three on the improvement in antibody titers, two on oxygen requirement, and two on adverse events. The pooled estimate for relative risk of death from SARS-CoV-2 was no different after CPT than control (RR: 0.87, 95% CI: 0.69, 1.10), (p = 0.426) but the relative risk of clinical improvement of symptoms was better after CPT (RR: 1.61, 95% CI: 0.97. 2.70). There was earlier hospital discharge after CPT over control (RR: 1.49, 95% CI: 0.79, 2.80), improved viral clearance (RR: 1.95; 95% CI: 1.07, 3.53), and quicker detection of antibody titer (RR: 1.95; 95% CI: 1.07, 3.53). No difference was observed for adverse effects between CPT and control (RR: 0.92.; 95% CI: 0.63 1.35). Conclusion: CPT appears to be a safe and promising treatment in moderate to severe SARS-CoV-2 leading to faster clinical improvement, reduced oxygen requirement, early hospital discharge, and quicker emergence of protective antibodies despite having no mortality benefit.

[1]  S. Hayat,et al.  Clinical characteristic and epidemiological features of SARS CoV‐2 disease patients from a COVID‐19 designated hospital in New Delhi , 2021, Journal of medical virology.

[2]  Shao-fei Yuan,et al.  Convalescent plasma may be a possible treatment for COVID-19: A systematic review , 2020, International Immunopharmacology.

[3]  D. Follmann,et al.  A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia , 2020, The New England journal of medicine.

[4]  T. Bhatnagar,et al.  Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) , 2020, BMJ.

[5]  Yaokai Chen,et al.  The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series , 2020, Signal Transduction and Targeted Therapy.

[6]  A. Abdulamir,et al.  The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. , 2020, Le infezioni in medicina.

[7]  H. Bach,et al.  Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks , 2020, Clinical Microbiology and Infection.

[8]  K. Soni,et al.  Convalescent plasma is a clutch at straws in COVID‐19 management! A systematic review and meta‐analysis , 2020, Journal of medical virology.

[9]  M. Salesi,et al.  Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study , 2020, Transfusion and Apheresis Science.

[10]  E. Wood,et al.  Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. , 2020, The Cochrane database of systematic reviews.

[11]  Hua He,et al.  A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease , 2020, International Journal of Infectious Diseases.

[12]  L. Ren,et al.  Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[13]  G. Guyatt,et al.  Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis , 2020, Canadian Medical Association Journal.

[14]  Luis Unigarro,et al.  Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review , 2020, Diagnostic Microbiology and Infectious Disease.

[15]  Luis Unigarro,et al.  Clinical, Molecular and Epidemiological Characterization of the SARS-CoV2 Virus and the Coronavirus Disease 2019 (COVID-19): A Comprehensive Literature Review , 2020 .

[16]  Wayne T. Nicholson,et al.  Deployment of convalescent plasma for the prevention and treatment of COVID-19. , 2020, The Journal of clinical investigation.

[17]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.